UBS’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History

UBS’s Portfolio MNTA Stock Details MNTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	$1.73M	Buy	152,100 +77,043	+103%	+$879K	﹤0.01%	3033
2014 Q2	$907K	Buy	75,057 +3,443	+5%	+$40.7K	﹤0.01%	3643
2014 Q1	$834K	Sell	71,614 -87,609	-55%	-$1.48M	﹤0.01%	3678
2013 Q4	$2.81M	Sell	159,223 -30,419	-16%	-$511K	﹤0.01%	2470
2013 Q3	$2.73M	Buy	189,642 +172,298	+993%	+$2.64M	﹤0.01%	2291
2013 Q2	$261K	Buy	+17,344	New	+$229K	﹤0.01%	4821

Other funds holding MNTA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

NTC

North Tide Capital Boston, Massachusetts $469M AUM 6.57% 1-Year Est. Return

DCM

Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

UBS's MNTA Position: Q3 2014 in Review

UBS increased its Momenta Pharmaceuticals, Inc. (MNTA) stake by 103% in Q3 2014, buying an estimated $879K and bringing the position to 152,100 shares worth $1.73M. The position accounts for ﹤0.01% of the portfolio, ranked #3033.

UBS first reported a position in MNTA in Q2 2013 and has held it in 6 quarters since. The position peaked at $2.81M in Q4 2013. 143 funds tracked by Wall St. Rank hold MNTA as of Q3 2014.

UBS held 152,100 shares of Momenta Pharmaceuticals, Inc. worth $1.73M as of Q3 2014.
UBS bought 77,043 Momenta Pharmaceuticals, Inc. shares in Q3 2014, an estimated $879K.
Momenta Pharmaceuticals, Inc. made up ﹤0.01% of UBS's portfolio in Q3 2014, its #3033 holding.
UBS first reported a position in Momenta Pharmaceuticals, Inc. in Q2 2013 and has held it in 6 quarters since.
UBS's Momenta Pharmaceuticals, Inc. position peaked at $2.81M in Q4 2013.
143 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.